tiprankstipranks
Immuneering (IMRX)
NASDAQ:IMRX
US Market

Immuneering (IMRX) Income Statement

Compare
336 Followers

Immuneering Income Statement

Last quarter (Q3 2024), Immuneering's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Immuneering's net income was $-14.60M. See Immuneering’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 0.00$ 316.95K$ 2.08M$ 2.31M$ 1.92M
Gross Profit
$ -764.14K$ 158.83K$ 926.89K$ 1.03M$ 696.74K
Operating Expenses
$ 57.65M$ 51.90M$ 34.81M$ 18.11M$ 6.99M
Depreciation and Amortization
$ 352.08K$ 796.79K$ 159.07K$ 79.31K$ 18.08K
EBITDA
$ -58.06M$ -51.47M$ -33.68M$ -17.00M$ -7.34M
Operating Income
$ -58.41M$ -51.74M$ -33.89M$ -17.08M$ -6.29M
Other Income/Expenses
$ 4.94M$ 1.23M$ 42.84K$ 42.66K$ -1.42M
Pretax Income
$ -53.47M$ -50.51M$ -33.84M$ -17.04M$ -7.71M
Net Income
$ -53.47M$ -49.28M$ -33.54M$ -17.04M$ -8.06M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -1.88$ -1.87$ -1.27$ -0.67$ -0.32
Diluted EPS
$ -1.88$ -1.87$ -1.27$ -0.67$ -0.32
Weighted Average Shares Outstanding
28.42M 26.39M 26.32M 25.51M 25.51M
Weighted Average Shares Outstanding (Diluted)
28.42M 26.39M 26.32M 25.51M 25.51M
Currency in USD

Immuneering Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis